Education
About Us
Working with TipRanks
Follow Us
Innovent Biologics (HK:1801)
:1801
1801 Stock Chart & Stats
HK$80.75
-HK$0.85(-2.50%)
At close: 4:00 PM EST
HK$80.75
-HK$0.85(-2.50%)
Day’s Range― - ―
52-Week RangeHK$28.65 - HK$109.10
Previous CloseN/A
Volume9.75M
Average Volume (3M)16.11M
Market Cap
HK$139.30B
Enterprise ValueHK$126.14B
Total Cash (Recent Filing)HK$9.54B
Total Debt (Recent Filing)HK$3.38B
Price to Earnings (P/E)108.7
Beta0.93
Next Earnings
Apr 01, 2026EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.56
Shares Outstanding1,720,801,000
10 Day Avg. Volume15,175,046
30 Day Avg. Volume16,110,837
Financial Highlights & Ratios
PEG Ratio6.48
Price to Book (P/B)4.26
Price to Sales (P/S)5.94
P/FCF Ratio-133.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$116.54Price Target Upside44.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial PerformanceInnovent reported significant revenue growth, achieving 51% of prior full-year forecasts and exceeding expectations.
Research And DevelopmentThe advancement of IBI363 towards global development with FDA clearance for a key trial marks a major milestone in its development.
Strategic PartnershipsInnovent has announced a global strategic partnership with Takeda on several key oncology assets, designed to expand Innovent’s global footprint.
Bears Say
Innovent Biologics News
1801 FAQ
What was Innovent Biologics’s price range in the past 12 months?
Innovent Biologics lowest stock price was HK$28.65 and its highest was HK$109.10 in the past 12 months.
What is Innovent Biologics’s market cap?
Innovent Biologics’s market cap is HK$139.30B.
When is Innovent Biologics’s upcoming earnings report date?
Innovent Biologics’s upcoming earnings report date is Apr 01, 2026 which is in 103 days.
How were Innovent Biologics’s earnings last quarter?
Innovent Biologics released its earnings results on Aug 27, 2025. The company reported HK$0.562 earnings per share for the quarter, beating the consensus estimate of HK$0.198 by HK$0.363.
Is Innovent Biologics overvalued?
According to Wall Street analysts Innovent Biologics’s price is currently Undervalued.
Does Innovent Biologics pay dividends?
Innovent Biologics does not currently pay dividends.
What is Innovent Biologics’s EPS estimate?
Innovent Biologics’s EPS estimate is 0.04.
How many shares outstanding does Innovent Biologics have?
Innovent Biologics has 1,720,801,000 shares outstanding.
What happened to Innovent Biologics’s price movement after its last earnings report?
Innovent Biologics reported an EPS of HK$0.562 in its last earnings report, beating expectations of HK$0.198. Following the earnings report the stock price went down -4.961%.
Which hedge fund is a major shareholder of Innovent Biologics?
Currently, no hedge funds are holding shares in HK:1801
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Innovent Biologics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
101.65%
12-Months-Change
Fundamentals
Return on Equity
8.41%
Trailing 12-Months
Asset Growth
17.88%
Trailing 12-Months
Company Description
Innovent Biologics
Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and esophageal carcinoma. The company also offers Byvasda for the treatment of several malignant tumors; Halpryza for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and Wegener's granulomatosis; Pemazyre for the treatment of adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib for the treatment of adult patients with tyrosine kinase inhibitor; and Cyramza to treat four different types of cancers. In addition, it engages in the development of IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein for ocular fundus disease; IBI-306, a human monoclonal antibody to treat hypercholesterolemia; IBI-310, a recombinant human anti CTLA-4 monoclonal antibody for liver cancer and renal cell carcinoma. Further the company develops IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for the treatment of adults with relapsed or refractory multiple myeloma; IBI-376 for the treatment of recurrent or refractory follicular lymphoma; and IBI-112 for the treatment of psoriasis. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. The company has strategic collaborations with NeoCura Bio-Medical Technology Co. Ltd.; Roche Group; Ascentage Pharma Group International; Eli Lilly and Company; Roche Group; and Bolt Biotherapeutics, Inc. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.
1801 Stock 12 Month Forecast
Average Price Target
HK$116.54
▲(44.32% Upside)
Technical Analysis
Sino Biopharmaceutical
―
Wuxi Biologics (Cayman)
―
Akeso, Inc.
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―
Options Prices
Currently, No data available
---